SCHEMBL613006

SCHEMBL613006

CCCNC(=O)c1c(Cl)cc(Cl)c(OC)c1[N+](=O)[O-]

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.47
GRIN2D O15399 1/20 0.41
GRIN3B O60391 1/20 0.41
GRIN1 Q05586 1/20 0.41
GRIN2A Q12879 1/20 0.41
GRIN2B Q13224 1/20 0.41
GRIN2C Q14957 1/20 0.41
GRIN3A Q8TCU5 1/20 0.41
ALDH1A1 P00352 2/20 0.40
POLB P06746 3/20 0.40
THRB P10828 1/20 0.40
RECQL P46063 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HPGD P15428 1/20 0.40
KDM4E B2RXH2 2/20 0.40
GAA P10253 1/20 0.40
PKM P14618 1/20 0.39
DRD3 P35462 3/20 0.39
DRD2 P14416 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31470179 0.83 SMN1; SMN2 (0.49) SMN1; SMN2GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL608700 0.80 SMN1; SMN2 (0.64) SMN1; SMN2GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL611961 0.78 PKM (0.50) SMN1; SMN2GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL8022533 0.75 G6PD (0.38) POLBHPGDGAAPKMKMT2A
SCHEMBL8037524 0.71 POLB (0.39) SMN1; SMN2ALDH1A1POLBTHRBRECQL
SCHEMBL7812037 0.70 NPC1 (0.52) ALDH1A1POLBTHRBRECQLTDP1
SCHEMBL10788683 0.70 POLB (0.63) SMN1; SMN2ALDH1A1POLBTHRBRECQL
SCHEMBL11644819 0.69 MGLL (0.51) ALDH1A1POLBTDP1PKMNPC1
SCHEMBL30739707 0.69 ALDH1A1 (0.46) SMN1; SMN2ALDH1A1POLBTHRBRECQL
SCHEMBL8038459 0.69 TRPV1 (0.39) SMN1; SMN2ALDH1A1HPGDTRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2379510-B1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LTD (AU) 2016-10-26 EP disclosed
US-20150359796-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2015-12-17 US disclosed
US-9145375-B2 Quinazolinone compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2015-09-29 US disclosed
US-20150025072-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2015-01-22 US disclosed
US-8889695-B2 Quinazolinone compounds PRANA BIOTECHNOLOGY LIMITED (AU) 2014-11-18 US disclosed
US-20120040980-A1 QUINAZOLINONE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150359796-A1 QUINAZOLINONE COMPOUNDS PARK7, SNCA, NDUFV2 SMN1; SMN2 354/4885GRIN2D 585/4885GRIN3B 245/4885
US-20150025072-A1 QUINAZOLINONE COMPOUNDS PARK7, SNCA, NQO2 SMN1; SMN2 525/4885GRIN2D 667/4885GRIN3B 266/4885
US-20120040980-A1 QUINAZOLINONE COMPOUNDS PARK7, SNCA, NQO2 SMN1; SMN2 525/4885GRIN2D 667/4885GRIN3B 266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.